|Articles|February 14, 2019
TARGET PharmaSolutions Launches Real-World Observational Study
Advertisement
TARGET PharmaSolutions, Inc., a company focused on real-world evidence, launched its latest large-scale observational study, TARGET-DERM. The study will deliver real-world evidence for several immune-mediated inflammatory skin conditions (IMISCs), initially focusing on patients with atopic dermatitis (AD/eczema). and vitiligo (loss of skin pigment).
Read the full release
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
The Data Harmonization Imperative: How AI Is Solving Clinical Research's Biggest Bottleneck
2
A Shot in the Arm to Traditional Vaccine Trial Strategy
3
SCOPE X: How AI Could Reshape the Sponsor-Site Relationship Over the Next Several Years
4
Patient Engagement Strategies in Anti-Obesity Medication Clinical Trials: Addressing Drop Out Rate and Improving Retention
5